KLRK1 and lymphoma: Additionally, NKG2D CAR-T cells have shown therapeutic efficacy not only in EBV-associated lymphomas (64) but also in human T-ALL (65), indicating that NKG2D-mediated immune recognition may provide a broadly applicable mechanism for tumor control in both virus-related and unrelated malignancies.